On Thursday, Trupanion hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 89 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary rating identifies price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an RS Rating north of 80 at the beginning of a new run.
Trupanion has risen more than 5% past a 36.66 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
Trupanion posted 0% earnings growth in the latest quarterly report. Revenue increased 12%.
Trupanion holds the No. 1 rank among its peers in the Insurance-Accident & Healthcare industry group. Unum Group and Oscar Health are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
